Wedbush Expects Increased Earnings for Avalo Therapeutics

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Research analysts at Wedbush lifted their Q1 2025 earnings estimates for Avalo Therapeutics in a report released on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of $0.63 for the quarter, up from their previous estimate of $0.55. Wedbush currently has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($19.07) per share.

A number of other equities research analysts have also weighed in on AVTX. BTIG Research started coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a "buy" rating and a $40.00 price objective for the company. Piper Sandler initiated coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an "overweight" rating and a $48.00 target price for the company. Stifel Nicolaus started coverage on Avalo Therapeutics in a research report on Tuesday. They set a "buy" rating and a $36.00 price target on the stock. HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Finally, Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They set a "buy" rating and a $23.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Avalo Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $33.00.

Remove Ads

Avalo Therapeutics Stock Performance

Shares of AVTX stock traded up $0.91 during mid-day trading on Friday, reaching $8.54. The company's stock had a trading volume of 300,368 shares, compared to its average volume of 211,173. Avalo Therapeutics has a 12-month low of $4.60 and a 12-month high of $34.46. The company's 50 day simple moving average is $7.51 and its 200-day simple moving average is $9.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Tower Research Capital LLC TRC lifted its stake in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after buying an additional 3,754 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Avalo Therapeutics in the 4th quarter worth about $114,000. Walleye Capital LLC bought a new stake in Avalo Therapeutics in the 4th quarter valued at about $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics during the 4th quarter valued at about $168,000. Finally, Bank of Montreal Can acquired a new position in Avalo Therapeutics during the 4th quarter valued at about $446,000. Institutional investors and hedge funds own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.